Most cited papers from Institut Paoli-Calmettes

Institut Paoli-Calmettes

What are the most cited papers from Institut Paoli-Calmettes?

The most cited paper from Institut Paoli-Calmettes is "CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma" (Bertrand Coiffier, Éric Lepage, Josette Brière et al., 2002), with 5,630 citations. Next come "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" (4,010) and "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial" (3,328).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 537 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma Bertrand Coiffier, Éric Lepage, Josette Brière et al. · New England Journal of Medicine Open access	24 Jan 2002	5,630
2	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms Rita Alaggio et al. · Leukemia Open access	22 Jun 2022	4,010
3	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Johann Sebastian De Bono, Stéphane Marie. Oudard, Mustafa Özgüroğlu et al. · The Lancet	Oct 2010	3,328
4	Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families Deborah Ford et al. · The American Journal of Human Genetics Open access	Mar 1998	3,057
5	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Thierry Conroy et al. · New England Journal of Medicine Open access	19 Dec 2018	2,918
6	A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma Michel Attal, Jean-Luc Harousseau, Anne-Marie Stoppa et al. · New England Journal of Medicine Open access	11 Jul 1996	2,583
7	International network of cancer genome projects Jennifer L. Jennings et al. · Nature Open access256 authors	13 Apr 2010	2,439
8	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation Jennifer Keating Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine Open access	15 Aug 2018	2,198
9	Defining the Intensity of Conditioning Regimens: Working Definitions Andrea Paolo Bacigalupo, Karen Kuhn Ballen, Doug Rizzo et al. · Transplantation and Cellular Therapy Open access	2 Sep 2009	1,845
10	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology	20 Oct 2010	1,556
11	Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program J Gäbert, Emmanuel Jean Beillard, Vincent H. J. van der Velden et al. · Leukemia	9 Oct 2003	1,540
12	Lipid metabolic reprogramming in cancer cells Sadia Beloribi‐Djefaflia, Sophie Vasseur, Fabienne Guillaumond · Oncogenesis Open access	25 Jan 2016	1,446
13	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Thomas B. Powles et al. · The Lancet Open access	18 Dec 2017	1,437
14	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease JJM van Dongen, EA Macintyre, J Gäbert et al. · Leukemia	Dec 1999	1,174
15	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma Michel Attal et al. · New England Journal of Medicine Open access	9 May 2012	1,165
16	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial Christophe Le Tourneau et al. · The Lancet Oncology	3 Sep 2015	1,144
17	The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): Update 2011 on non-hepatic applications Fabio Piscaglia et al. · Ultraschall in der Medizin - European Journal of Ultrasound Open access	26 Aug 2011	1,085
18	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Gilles Salles et al. · The Lancet	21 Dec 2010	1,081
19	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Philippe Moreau et al. · New England Journal of Medicine Open access	27 Apr 2016	1,067
20	Breast cancer prognostic classification in the molecular era: the role of histological grade Emad A. Rakha, Jorge Sergio Reis-Filho, Frederick L. Baehner et al. · Breast Cancer Research Open access	30 Jul 2010	1,017
21	Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma Michel Attal, Jean-Luc Harousseau, Thierry T.F. Facon et al. · New England Journal of Medicine	24 Dec 2003	979
22	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Philippe Moreau et al. · The Lancet Open access	3 Jun 2019	973
23	Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial John Burn et al. · The Lancet Open access	28 Oct 2011	959
24	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism Thomas Farge et al. · Cancer Discovery Open access	17 Apr 2017	941
25	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Hervé Avet‐Loiseau et al. · Blood Open access	5 Jan 2007	917
26	Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program Emmanuel Jean Beillard, Niels Pallisgaard, Vincent H. J. van der Velden et al. · Leukemia	9 Oct 2003	887
27	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome Grazia Arpino, Valerie Jeanne H. Bardou, Gary M. Clark et al. · Breast Cancer Research Open access	17 Feb 2004	880
28	Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome Nicholas Hearle et al. · Clinical Cancer Research	15 May 2006	861
29	Targeting natural killer cells and natural killer T cells in cancer Eric D. Vivier, Sophie Ugolini, Didier Blaise et al. · Nature reviews. Immunology ReviewOpen access	22 Mar 2012	845
30	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial Valérie Vilgrain et al. · The Lancet Oncology 140 authors	26 Oct 2017	841
31	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design Karim S. Fizazi et al. · The Lancet Open access	Apr 2022	823
32	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses David Cameron et al. · Breast Cancer Research and Treatment	10 Jan 2008	810
33	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study Philip James Johnson et al. · Journal of Clinical Oncology	27 Aug 2013	780
34	Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor Hideyuki Ikeda, Bernard Lethé, Frédéric François Lehmann et al. · Immunity Open access	Feb 1997	777
35	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts Christophe Ginestier, Suling Liu, Mark E. Diebel et al. · Journal of Clinical Investigation Open access	7 Jan 2010	751
36	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology	Nov 2012	748
37	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Gwénaëlle Gravis et al. · The Lancet Oncology	8 Jan 2013	747
38	Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24 Brent W. Zanke et al. · Nature Genetics	8 Jul 2007	731
39	Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations Sunil R. Lakhani et al. · JNCI Journal of the National Cancer Institute	5 Aug 1998	708
40	Endoscopic Ultrasound-Guided Bilioduodenal Anastomosis: A New Technique for Biliary Drainage Marc Giovannini, Vincent Moutardier, Christian Pésenti et al. · Endoscopy	20 Sep 2001	706
41	Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity Émilie Mamessier, Aude Sylvain, Marie‐Laure Thibult et al. · Journal of Clinical Investigation Open access	15 Aug 2011	693
42	The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans Cameron S. Brandt, Myriam Baratin, Eugene C. Yi et al. · The Journal of Experimental Medicine Open access	15 Jun 2009	690
43	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists Sunil Badve, David J. Dabbs, Stuart J. Schnitt et al. · Modern Pathology Open access	15 Nov 2010	685
44	Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline Pier Alberto Testoni, Alberto Mariani, Lars Aabakken et al. · Endoscopy Open access	14 Jun 2016	671
45	Allogeneic hematopoietic cell transplantation for metastatic breast cancer Naoto Tada Ueno, J. Douglas Rizzo, Taner Demirer et al. · Bone Marrow Transplantation	17 Dec 2007	658
46	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions Andrew Kenneth Burroughs, Jean‐François Dufour, Peter R. Galle et al. · Seminars in Liver Disease Open access	8 Feb 2013	648
47	The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells Laurence de Leval, David S. Rickman, Caroline Thielen et al. · Blood	7 Feb 2007	633
48	Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond Mohamad Mohty · Leukemia	5 Apr 2007	618
49	Phytoestrogen Interaction with Estrogen Receptors in Human Breast Cancer Cells* Pierre Martin, Kathryn B. Horwitz, Dale S. Ryan et al. · Endocrinology	Nov 1978	605
50	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Thomas B. Powles et al. · Nature Medicine Open access	Nov 2019	585

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.